Adverum reports positive 24-week data from first cohort of OPTIC phase 1 ttrial
Adverum Biotechnologies announced positive 24-week clinical data from the first cohort of patients treated with a one-time intravitreal dose of ADVM-022 in the OPTIC phase 1 clinical trial in wet age-related macular degeneration. ADVM-022 was safe and well tolerated. September 12, 2019